Tests pembrolizumab with low-dose cyclophosphamide in melanoma that stopped responding to immunotherapy
Tests pembrolizumab with low-dose cyclophosphamide in adults with melanoma after checkpoint inhibitor treatment.
Key facts
- Who runs it
- University of California, Irvine
- Where
- Orange, United StatesSee the site
- Trial code
- Registry title
- Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 14 people, planned
- Started
- 23 Dec 2024
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- Pembrolizumab
- Cyclophosphamide
- Record updated
- 10 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma that cannot be removed by surgery (stage III or IV, not in the eye) and that kept growing after earlier PD-1/PD-L1 immunotherapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Unresectable stage III or stage IV non-ocular melanoma that cannot be treated with local therapy. Measurable disease by RECIST v1.1. ECOG performance status 0, 1 or 2. Life expectancy of at least 12 weeks.
- Earlier treatment
- The cancer must have progressed on earlier PD-1/PD-L1 treatment, given within 9 weeks before the first dose. Side effects from pembrolizumab must have settled to Grade 1 or less (hormone-related effects excepted).
- Biomarker or test result
- People with a B-RAF driver mutation must have had BRAF +/- MEK inhibitors first, unless they decline them or cannot tolerate them.
Main reasons for not taking part
- Eye (ocular) melanoma or metastatic uveal melanoma
- Untreated or symptomatic brain or spinal cord (CNS) metastases
- Another cancer in the past, with a few exceptions such as cancers treated and not returned for 2 years
- Serious side effect (grade 3 or greater) from earlier PD-1/PD-L1 treatment, or unable to be treated with pembrolizumab again
- Past solid organ or allogeneic tissue transplant, or being pregnant or breastfeeding
The registry criteria, word for word
Show all 42 criteriaShow less
Who can take part
- Age ≥18 years at the time of signing informed consent form (ICF)
- Patients must have unresectable Stage III or Stage IV non-ocular melanoma per American Joint Committee on Cancer 8th Edition Staging Criteria not amenable to local therapy
- Participants must have measurable disease by RECIST v1.1 criteria as assessed by investigator/ radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions
- Participants must have Eastern Cooperative Group (ECOG) performance status score of 0, 1 or 2 at screening visit
- Life expectancy of at least 12 weeks
- Adequate bone marrow, liver, and renal function
- Hemoglobin ≥9.0 g/dL
- Platelets ≥100/mm3
- ANC ≥1.5/mm3
- Creatinine Clearance ≥ 30mL/min Cockcroft-Gault CrCl, mL/min = (140 - age) × (weight, kg) × (0.85 if female) / (72 × Cr, mg/dL)
- AST and ALT less than 3 times the Upper Limit of Normal or less than 5 times the Upper Limit of normal with liver metastases. T Bilirubin < 3.1 mg/dL
- Has progressed on a prior PD-1/PD-L1 treatment
- Recovered from toxicities of pembrolizumab to Grade ≤1, excluding endocrine toxicities
- Prior Receipt of PD-1/PD-L1 therapy within 9 weeks prior to the first dose of the investigational therapy
- Women of childbearing potential must have had a negative pregnancy test performed within 7 days prior to the start of treatment
- Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study
- Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 3 months after the final dose of study intervention; cessation of birth control after this point shall be discussed with a responsible physician
- Pregnant or lactating women are prohibited from enrolling in this study
- Male participants are not allowed to donate sperm from the time of enrollment until 6 months after administration of study interventions
Who cannot take part
- Participants ineligible to be retreated with pembrolizumab due to a treatment-related AE while on a prior anti-PD(L)-1 regimen that led to discontinuation of that prior therapy and would thus prevent retreatment or with an immune-related adverse event (irAE) of grade 3 or greater
- Participants with known untreated or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. NOTE: Participants with previously treated brain metastases may participate provided ALL of the following apply:
- Treated CNS lesions are radiographically stable (without evidence of progression for ≥ 28 days prior to the first dose of study intervention) after intervention (eg, surgery and/or radiation)
- Neurologically stable and on stable dose of ≤ 10mg of prednisone equivalent steroids for at least 7 days prior to the first dose of study intervention
- Any prior investigational or standard cancer therapy, with exception of PD-1/PD-L1 (includes nivolumab + Relatlimab) therapy, chemotherapy or radiation within 6-9 weeks of the first dose of the investigational therapy (see Inclusion Criteria)
- Presence of B-RAF driver mutation without prior receipt of BRAF +/- MEK inhibitors, unless patient declines BRAF +/-MEK inhibition for any reason or is unable to tolerate BRAF and/or MEK inhibitors
- Known HBV infection defined as hepatitis B surface antigen reactive. NOTE: Participants with HBV infection on stable anti-viral therapy for > 4 weeks prior to the planned first study intervention and viral load confirmed as undetectable during Screening may be eligible
- Known active HCV infection defined as detectable HCV RNA (qualitative) infection. NOTE: History of HCV is not exclusionary if participant has received curative treatment and viral load is confirmed as undetectable during Screening
- Participants with a history of a malignant disease other than those being treated in this study. The following exceptions are permitted:
- Malignancies that were treated curatively and have not recurred within 2 years. Shorter intervals can be considered after discussion with the Principal Investigator
- Completely resected basal cell and squamous cell skin cancers
- Any malignancy considered to be indolent and that has never required therapy, such as chronic lymphocytic leukemia
- Participants with a known history of chronic viral infections as indicated below. If patients do not have a known history, testing is not required during the screening period to confirm the patient has an active infection
- Glomerular filtration rate (calculated using the Chronic Kidney Disease Epidemiology Collaboration formula) < 30 mL/min
- Participants with a history of allogeneic tissue/solid organ transplant
- Active HIV infection. Those with HIV infections on combination antiretroviral medications with stable CD4 count >200/microliters as measured within screening time period. If the patient does not have a known history of HIV, then testing is not required during screening to confirm presence or absence of HIV
- Positive serum pregnancy test
- Participants with out-of-range screening laboratory values as defined below. NOTE: Hematology evaluations must be performed >7 days from any blood transfusion. Or blood product transfusion or from any dose of hematologic growth factor
- Total bilirubin > 1.5 × ULN; participants with Gilbert's syndrome are excluded if total bilirubin > 3.0 × ULN; or direct bilirubin > 1.5 × ULN
- Albumin < 3.0 g/dL
- Absolute lymphocyte count < 0.5 × 10\^9/L
- Participants with a diagnosis of ocular or metastatic uveal melanoma
- Completely resected carcinoma in situ of any type
Where in United States
- Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, United StatesContact: Warren Chow, MDTaking people
About the trial
What the trial wants to find out
This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.
The group in the trial
- Pembrolizumab + CyclophosphamideTreatment being tested
Pembrolizumab 200mg IV every 21 days or 400 mg IV every 42 days Cyclophosphamide 50mg PO daily on days 1-14 every 21 days for melanoma patients
Treatment: Pembrolizumab and Cyclophosphamide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
- Plain-language title
- Tests pembrolizumab with low-dose cyclophosphamide in melanoma that stopped responding to immunotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 March 2026